Skip to content
Open access

From Therapeutic Nihilism to Precision Hepatology: Resmetirom and Semaglutide as Catalysts for a New Era in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Management

Nov 2026 · Livers · 0 citations · 22 references

Abstract

The publication of the joint EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy represents a watershed moment in hepatology [...]

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.